Hims & Hers Health (HIMS) Convertible Debt (2025 - 2026)
Hims & Hers Health's (HIMS) quarterly Convertible Debt came in at $974.1 million in Q1 2026, little changed quarter-over-quarter from $972.6 million in Q4 2025.
Hims & Hers Health (HIMS) Convertible Debt (2025 - 2026) Analysis & Trends
Hims & Hers Health has disclosed Convertible Debt across 2 years of filings, most recently posting $974.1 million for Q1 2026.
- Convertible Debt for Q1 2026 came in at $974.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $974.1 million (changed N/A YoY), and the FY2025 annual result was $972.6 million, changed N/A from the prior year.
- Convertible Debt came in at $974.1 million for Q1 2026 at Hims & Hers Health, roughly flat from $972.6 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $974.1 million in Q1 2026 to a low of $969.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 974.11 Mn |
| Dec 31, 2025 | 972.58 Mn |
| Sep 30, 2025 | 971.02 Mn |
| Jun 30, 2025 | 969.47 Mn |